LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

Amathus Therapeutics

Amathus Therapeutics is developing first-in-class small molecule therapeutics targeting organelle-specific molecular chaperones to harness the benefit of positively modulating cellular stress responses.   Our lead programs enhance mitochondrial function and are in development for Parkinson’s disease and renal disorders. 

Amathus Therapeutics logo
Website - Coming Soon
  • Yiannis Ioannou, PhD Founder & Chair, Scientific Advisory Board
  • David Weiner, MD Chief Executive Officer
  • Ed Holson, PhD Chief Scientific Officer